Tango Therapeutics Inc Aktie News

BOSTON, 03. Sept. 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics oder das Unternehmen) gab heute bekannt, dass mit Wirkung zum 1. September 2026 der Vergütungsausschuss des Vorstands von Tango Therapeutics einem neuen Mitarbeiter im Rahmen des 2023 Inducement Plan des Unternehmens eine nicht qualifizierte Aktienoption zum Kauf von 146.500 Aktien seiner Stam...

BOSTON, 06. Aug. 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), ein biotechnologisches Unternehmen im klinischen Stadium, das sich der Entdeckung und Bereitstellung der nächsten Generation präziser Krebsmedikamente verschrieben hat, gab heute bekannt, dass Dr. Barbara Weber, Executive Chairman des Verwaltungsrats von Tango Therapeutics, im Zusammenhang mit anderen Tätigkeiten...

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, in...

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stoc...

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the “Offering”) of $500 million of its common stock. All shares of common stock to be sold in the Offering will...

Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, vopimetostat. The drug was tested in combination with Revolution Medicines' daraxonrasib.

Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.

Tango Therapeutics stock skyrocketed Monday after the biotech company added to the Revolution Medicines's results in pancreatic cancer.